Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV a cohort study

Annals of Internal Medicine

Volumn 162, Issue 2, 2015, Pages 90-99

  Katz, Ingrid T ^a   Leister, Erin ^b   Kacanek, Deborah ^b   Hughes, Michael D ^b   Bardeguez, Arlene ^c   Livingston, Elizabeth ^d   Stek, Alice ^e   Shapiro, David E ^b   Tuomala, Ruth ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RITONAVIR; VIRUS RNA;

ARTICLE; DELIVERY; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTIPARA; NULLIPARA; PATIENT COMPLIANCE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RISK FACTOR; THIRD TRIMESTER PREGNANCY; VIRUS INHIBITION; ADOLESCENT; ADULT; BLOOD; CLINICAL TRIAL; ETHNOLOGY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; PARITY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PREVENTION AND CONTROL; TIME FACTOR; VERTICAL TRANSMISSION; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EDUCATIONAL STATUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MEDICATION ADHERENCE; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; PRENATAL CARE; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84921688899     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2005     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. STDs & Pregnancy- CDC fact sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessed at www.cdc.gov/std/pregnancy/stdfact-pregnancy.htm on 12 November 2014.
2. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402. [PMID: 10432324].
3. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385-93. [PMID: 10432323].
4. Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 1999;179:590-9. [PMID: 9952365].
5. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. The European Collaborative Study. AIDS. 1999;13:1377-85. [PMID: 10449292].
6. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-65. [PMID: 15668871].
7. Choo V. Maternal transmission of HIV. Lancet. 1994;343:533. [PMID: 7906769].
8. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331:1173-80. [PMID: 7935654].
9. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-94. [PMID: 11981365].
10. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007:CD003510. [PMID: 17253490].
11. Peters V, Liu KL, Dominguez K, Frederick T, Melville S, Hsu HW, et al. Missed opportunities for perinatal HIV prevention among HIVexposed infants born 1996-2000, pediatric spectrum of HIV disease cohort. Pediatrics. 2003;111:1186-91. [PMID: 12728136].
12. Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, et al. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDSdefining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS. 2010;24:279- 86. [PMID: 20438375] doi:10.1089/apc.2009.0283.
13. Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, et al; Aids Clinical Trials Group ACTG A5150 Team. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011;12:9-23. [PMID: 21388937] doi:10.1310/hct1201-9.
14. Izzo I, Forleo MA, Casari S, Quiros-Roldan E, Magoni M, Carosi G, et al. Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: A single-cohort observational study (Brescia, Northern Italy). BMC Public Health. 2011;11:124. [PMID: 21338498] doi:10.1186/1471-2458-11-124.
15. Joao EC, Gouvêa MI, Menezes JA, Sidi LC, Cruz ML, Berardo PT, et al. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil. Int J STD AIDS. 2012;23: 44-7. [PMID: 22362687] doi:10.1258/ijsa.2011.010545.
16. Patel D, Cortina-Borja M, Thorne C, Newell ML; European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647-56. [PMID: 17516411].
17. Okonji JA, Zeh C, Weidle PJ, Williamson J, Akoth B, Masaba RO, et al. CD4, viral load response, and adherence among antiretroviralnaive breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya. J Acquir Immune Defic Syndr. 2012;61:249-57. [PMID: 22692094].
18. Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr. 2010;54:27- 34. [PMID: 20065861] doi:10.1097/QAI.0b013e3181caea89.
19. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362:2282-94. [PMID: 20554983] doi: 10.1056/NEJMoa0907736.
20. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al; P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010;201:1035- 44. [PMID: 20196654] doi:10.1086/651232.
21. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19. [PMID: 1361652].
22. Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al; PACTG 1025 Protocol Team. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48:408-17. [PMID: 18614923] doi:10.1097/QAI.0b013e31817bbe80.
23. Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, et al; London HIV Perinatal Research Group. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS. 2012;26:1095-103. [PMID: 22441248] doi: 10.1097/QAD.0b013e3283536a6c.
24. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Bethesda, MD: National Institutes of Health; 2012: 1-235.
25. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: A prospective descriptive study. Lancet. 2007;369:1440-51. [PMID: 17467514].
26. Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et al. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr. 2012;58:505-8. [PMID: 22555385] doi:10.1093/tropej/fms019.
27. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000;96: 3866-71. [PMID: 11090071].
28. Heresi GP, Caceres E, Atkins JT, Reuben J, Doyle M. Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: An exception to the AIDS surveillance case definition. Clin Infect Dis. 1997;25:739-40. [PMID: 9314473].
29. Abramczuk BM, Mazzola TN, Moreno YM, Zorzeto TQ, Quintilio W, Wolf PS, et al. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol. 2011;18: 1406-9. [PMID: 21775515] doi:10.1128/CVI.05065-11.
30. Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM, Reis-Alves SC, et al. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infect Dis. 2011;11:38. [PMID: 21291536] doi:10.1186/1471-2334-11-38.
31. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-26. [PMID: 19339714] doi:10.1056/NEJMoa 0807252.
32. Leisegang R, Nachega JB, Hislop M, Maartens G. The impact of pregnancy on adherence to and defaulting from ART [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 27 February-2 March 2011. Abstract no. 1021.
33. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-3. [PMID: 11416722].
34. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIVinfected adults. AIDS. 2011;25:2177-81. [PMID: 21832935] doi: 10.1097/QAD.0b013e32834b6464.
35. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-73. [PMID: 17438315].
36. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. [PMID: 10877736].
37. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: A systematic review. PLoS Med. 2011;8:e1001056. [PMID: 21811403] doi:10.1371/journal.pmed .1001056.
38. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308:387-402. [PMID: 22820792] doi:10.1001/jama.2012.7961.
39. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, Giorgi JV, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr. 2000;24:218-26. [PMID: 10969345].
40. Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A, et al. The impact of race/ethnicity on motherto- child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr. 2004; 36:800-7. [PMID: 15213563].
41. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16:1139-46. [PMID: 12004272].
42. Thorburn S, Bogart LM. African American women and family planning services: perceptions of discrimination. Women Health. 2005;42:23-39. [PMID: 16418120].
43. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr. 2005;38:213-8. [PMID: 15671808].
44. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, et al; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA. 2006;296:769-81. [PMID: 16905783].
45. Cunningham WE, Hays RD, Duan N, Andersen R, Nakazono TT, Bozzette SA, et al. The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States. J Health Care Poor Underserved. 2005;16:655-76. [PMID: 16311491].
46. Shacham E, Nurutdinova D, Onen N, Stamm K, Overton ET. The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic population. AIDS Patient Care STDS. 2010;24:229-35. [PMID: 20397898] doi:10.1089/apc.2009 .0275.
47. Kalichman SC, Grebler T. Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS. Psychosom Med. 2010;72:810-6. [PMID: 20716711] doi: 10.1097/PSY.0b013e3181f01be3.
48. Osborn CY, Paasche-Orlow MK, Davis TC, Wolf MS. Health literacy: An overlooked factor in understanding HIV health disparities. Am J Prev Med. 2007;33:374-8. [PMID: 17950402].
49. Paasche-Orlow MK, Cheng DM, Palepu A, Meli S, Faber V, Samet JH. Health literacy, antiretroviral adherence, and HIV-RNA suppression: A longitudinal perspective. J Gen Intern Med. 2006;21: 835-40. [PMID: 16881943].